ZIOPHARM Oncology

NASDAQ: ZIOP
$3.32
+$0.12 (+3.8%)
Closing price August 7, 2020
Friday's top analyst upgrades and downgrades included Darden Restaurants, DuPont, EOG Resources, Lululemon Athletica, Micron Technology, Occidental Petroleum, Slack, Spotify, Ulta Beauty and Walt...
Four pharmaceutical makers posted new 52-week lows Tuesday: Ohr Pharma, Axovant Sciences, Axsome Therapeutics, and Ziopharm Oncology.
The top analyst upgrades, downgrades and other research calls seen on Thursday include Analog Devices, BP, First Data, General Electric, Goodyear, Illinois Tool Works, NRG Energy and Palo Alto...
Ziopharm Oncology saw its shares slide early on Friday after the company announced the pricing of its secondary offering.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Eldorado Gold, SLM, SunPower, Disney, Yelp and Myriad Genetics.
July 25, 2016: Here are four stocks trading with heavy volume among 18 equities making new 52-week lows in Monday’s session. NYSE decliners led advancers by about 2 to 1 and Nasdaq decliners...
July 22, 2016: Here are three stocks trading with heavy volume among 13 equities making new 52-week lows in Friday’s session. NYSE advancers led decliners by about 2 to 1 and Nasdaq advancers...
July 19, 2016: Here are four stocks trading with relatively heavy volume among 16 equities making new 52-week lows in Tuesday’s session. NYSE decliners led advancers by about 3 to 2 and Nasdaq...
Even though the market made incredible gains this past week, a few companies held it back from pushing even higher.
The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these...
Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs, due to positive trial results and an FDA meeting.
If you missed the biotech run and want to try to catch the train this late in the game, it would be wise not to use the new Proshares leveraged biotech ETFs.
The stock market continues to act like an aging prize fighter, one that will not give up despite all the haymakers landed. In keeping with the bullish tone, insiders continue buying stock.
When two stocks run up over 50% and 30% on the same news, investors have to wonder if the move in the stock was justified or if the news-pop was due to trading factors and sentiment.